Get all premium features to the best stock analysis tool

CAH's turnaround gains traction with strong earnings growth and margin expansion, outpacing MCK's steady performance outlook.

McKesson's strong oncology, GLP-1, and biopharma growth fuel earnings momentum, but margin pressure and segment volatility remain key watch points.

IRVING, Texas--(BUSINESS WIRE)--Registration is now open for McKesson ideaShare 2026, a premier community pharmacy event for independent pharmacy owners and their teams.

Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.

McKesson (MCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

McKesson Corporation (MCK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript